Andrew D. Seidman, MD, and Meredith M. Regan, ScD, on Breast Cancer: Results From the TEXT and SOFT Trials
2018 ASCO Annual Meeting
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discuss study findings on absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, HER2-negative breast cancer (Abstract 503).
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).
Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinomas (Abstract LBA4001).
Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center, discusses study findings on the effect of acupuncture vs cognitive behavior therapy in cancer survivors experiencing insomnia (Abstract 10001).
Juliet Elizabeth Wolford, MD, on Ovarian Cancer: The Cost of Care
Juliet Elizabeth Wolford, MD, of the University of California, Irvine, discusses the cost-effectiveness of various types of maintenance therapy in advanced ovarian cancer: paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab (Abstract 5508).
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.
